Literature DB >> 24267969

Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design.

Avani S Dholakia1, Rachit Kumar, Siva P Raman, Joseph A Moore, Susannah Ellsworth, Todd McNutt, Daniel A Laheru, Elizabeth Jaffee, John L Cameron, Phuoc T Tran, Robert F Hobbs, Christopher L Wolfgang, Joseph M Herman.   

Abstract

PURPOSE: To generate a map of local recurrences after pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDA) and to model an adjuvant radiation therapy planning treatment volume (PTV) that encompasses a majority of local recurrences. METHODS AND MATERIALS: Consecutive patients with resectable PDA undergoing PD and 1 or more computed tomography (CT) scans more than 60 days after PD at our institution were reviewed. Patients were divided into 3 groups: no adjuvant treatment (NA), chemotherapy alone (CTA), or chemoradiation (CRT). Cross-sectional scans were centrally reviewed, and local recurrences were plotted to scale with respect to the celiac axis (CA), superior mesenteric artery (SMA), and renal veins on 1 CT scan of a template post-PD patient. An adjuvant clinical treatment volume comprising 90% of local failures based on standard expansions of the CA and SMA was created and simulated on 3 post-PD CT scans to assess the feasibility of this planning approach.
RESULTS: Of the 202 patients in the study, 40 (20%), 34 (17%), and 128 (63%) received NA, CTA, and CRT adjuvant therapy, respectively. The rate of margin-positive resections was greater in CRT patients than in CTA patients (28% vs 9%, P=.023). Local recurrence occurred in 90 of the 202 patients overall (45%) and in 19 (48%), 22 (65%), and 49 (38%) in the NA, CTA, and CRT groups, respectively. Ninety percent of recurrences were within a 3.0-cm right-lateral, 2.0-cm left-lateral, 1.5-cm anterior, 1.0-cm posterior, 1.0-cm superior, and 2.0-cm inferior expansion of the combined CA and SMA contours. Three simulated radiation treatment plans using these expansions with adjustments to avoid nearby structures were created to demonstrate the use of this treatment volume.
CONCLUSIONS: Modified PTVs targeting high-risk areas may improve local control while minimizing toxicities, allowing dose escalation with intensity-modulated or stereotactic body radiation therapy.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24267969      PMCID: PMC3971882          DOI: 10.1016/j.ijrobp.2013.09.005

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  28 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

Authors:  C J Yeo; R A Abrams; L B Grochow; T A Sohn; S E Ord; R H Hruban; M L Zahurak; W C Dooley; J Coleman; P K Sauter; H A Pitt; K D Lillemoe; J L Cameron
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

3.  Radiobiology of stereotactic body radiation therapy/stereotactic radiosurgery and the linear-quadratic model.

Authors:  Chang W Song; L Chinsoo Cho; Jianling Yuan; Kathryn E Dusenbery; Robert J Griffin; Seymour H Levitt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-04-19       Impact factor: 7.038

4.  Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.

Authors:  Albert C Koong; Erin Christofferson; Quynh-Thu Le; Karyn A Goodman; Anthony Ho; Timothy Kuo; James M Ford; George A Fisher; Ralph Greco; Jeffrey Norton; George P Yang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-01       Impact factor: 7.038

5.  Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy.

Authors:  J Tepper; G Nardi; H Sutt
Journal:  Cancer       Date:  1976-03       Impact factor: 6.860

6.  Patterns of failure after curative resection of pancreatic carcinoma.

Authors:  J F Griffin; S R Smalley; W Jewell; J C Paradelo; R D Reymond; R E Hassanein; R G Evans
Journal:  Cancer       Date:  1990-07-01       Impact factor: 6.860

7.  Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.

Authors:  M H Kalser; S S Ellenberg
Journal:  Arch Surg       Date:  1985-08

Review 8.  Pancreatic cancer.

Authors:  Donghui Li; Keping Xie; Robert Wolff; James L Abbruzzese
Journal:  Lancet       Date:  2004-03-27       Impact factor: 79.321

9.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma.

Authors:  M Wagner; C Redaelli; M Lietz; C A Seiler; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2004-05       Impact factor: 6.939

10.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

View more
  20 in total

Review 1.  [Clinical target volume : Principles and limits].

Authors:  T B Brunner; M Walke; P Hass
Journal:  Radiologe       Date:  2018-08       Impact factor: 0.635

2.  Patency rates of portal vein/superior mesenteric vein reconstruction after pancreatectomy for pancreatic cancer.

Authors:  A N Krepline; K K Christians; K Duelge; A Mahmoud; P Ritch; B George; B A Erickson; W D Foley; E J Quebbeman; K K Turaga; F M Johnston; T C Gamblin; D B Evans; S Tsai
Journal:  J Gastrointest Surg       Date:  2014-09-17       Impact factor: 3.452

3.  Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.

Authors:  Joseph M Herman; Salma K Jabbour; Steven H Lin; Matthew P Deek; Charles C Hsu; Elliot K Fishman; Sinae Kim; John L Cameron; Marina Chekmareva; Daniel A Laheru; Amol K Narang; Timothy M Pawlik; Ralph H Hruban; Christopher L Wolfgang; Christine A Iacobuzio-Donahue
Journal:  Pancreas       Date:  2018-02       Impact factor: 3.327

Review 4.  Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.

Authors:  Cédric Panje; Nikolaus Andratschke; Thomas B Brunner; Maximilian Niyazi; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2016-10-24       Impact factor: 3.621

Review 5.  Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?

Authors:  Michael D Chuong; Drexell H Boggs; Kruti N Patel; William F Regine
Journal:  J Gastrointest Oncol       Date:  2014-06

6.  Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.

Authors:  Christina L Roland; Anthony D Yang; Matthew H G Katz; Deyali Chatterjee; Huamin Wang; Heather Lin; Jean N Vauthey; Peter W Pisters; Gauri R Varadhachary; Robert A Wolff; Christopher H Crane; Jeffrey E Lee; Jason B Fleming
Journal:  Ann Surg Oncol       Date:  2014-10-29       Impact factor: 5.344

7.  Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis.

Authors:  K Rangarajan; P H Pucher; T Armstrong; A Bateman; Zzr Hamady
Journal:  Ann R Coll Surg Engl       Date:  2019-07-15       Impact factor: 1.891

8.  Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma.

Authors:  Nikhil Yegya-Raman; Mihir M Shah; Miral S Grandhi; Elizabeth Poplin; David A August; Timothy J Kennedy; Usha Malhotra; Kristen R Spencer; Darren R Carpizo; Salma K Jabbour
Journal:  Ann Pancreat Cancer       Date:  2018-08-06

Review 9.  Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new.

Authors:  John Boyle; Brian Czito; Christopher Willett; Manisha Palta
Journal:  J Gastrointest Oncol       Date:  2015-08

10.  Mapping of local recurrence after pancreaticoduodenectomy for distal extrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy.

Authors:  Wonguen Jung; Kyubo Kim; Seog Ki Min; Eun Mi Nam; Jeong Kyong Lee
Journal:  Br J Radiol       Date:  2019-06-14       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.